67.9 F
San Diego
Thursday, Apr 18, 2024
-Advertisement-

Abide to Receive $50M Upfront in Collaboration with Celgene Corp.

Privately held Abide Therapeutics Inc. has partnered with biotech titan Celgene Corp. to develop new drugs in inflammation and immunology, receiving $50 million upfront in the deal.

The Princeton, N.J.-based Celgene has taken a small equity stake in Abide, and has received the exclusive option to acquire Abide.

San Diego-based Abide has also received $10 million in Series B funding from its original investor, Cardinal Partners. Abide was founded in 2011, and its enzyme-based therapies are based on research from The Scripps Research Institute. Its most advanced drug candidate, called AB101131, is expected to enter clinical trials in 2015.

-Advertisement-

Featured Articles

Hair Today, Hair Tomorrow

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-